A structure-based virtual screening of commercial compounds was carried out on the HCV NS3 helicase structure, with the aim to identify novel inhibitors of HCV replication. Among a selection of 13 commercial structures, one compound was found to inhibit the subgenomic HCV replicon in the low micromolar range. Different series of new piperazine-based analogues were designed and synthesized, and among them, several novel structures exhibited antiviral activity in the HCV replicon assay. Some of the new compounds were also found to inhibit HCV NS3 helicase function in vitro, and one directly bound NS3 with a dissociation constant of 570 ± 270 nM.
Introduction
The hepatitis C virus (HCV) is a major cause of chronic liver disease because it infects approximately 3% of the global population [1] . HCV infection becomes chronic in 60-85% of patients, who are at high risk of developing hepatic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma [2, 3] . An HCV vaccine is currently not available, while the standard of care for many years was a combination of pegylated interferon (pegIFN) and ribavirin, a therapy that was not specific for HCV, was effective in Figure 1 : NS3 helicase domains and binding sites within the 3KQN crystal structure [25] .
As revealed in several crystal structures available for the enzyme in complex with ssDNA or ssRNA oligonucleotides [25, 26] , the nucleic acid is bound within the closed conformation of the enzyme in a narrow central space defined by the three main domains (Figure 1 ). Due to the essential role demonstrated for Thr269, Arg393, Thr411 and Trp501 [27] , computer-based studies were directed to identify compounds binding the region defined by these residues. In particular, the sub-site defined by Trp501 and Arg393 in the 3KQN crystal structure [25] was used for the virtual screening of the SPECS library of commercial compounds [28] . The approximately 450,000 structures available were analysed with MOE 2014.10 conformational search tool [29] ; 500 low-energy conformations were kept for each input molecule. The main interactions between the target residues and the co-crystallised substrate were considered to build a pharmacophoric query, and the selection was restricted to five features (Figure 2 ). interact with Trp501 (green), a hydrogen-bond acceptor or anion group to interact with Gly255 and Thr269 (orange), a H-bond donor to target Asp296 (purple), a H-bond donor and acceptor to interact with Thr298 and Ser297 (yellow) and a hydrogen-bond acceptor to target Arg393 (blue). Exclusion volumes are hidden for clarity.
The 3,500 molecules matching the search criteria were further analysed with a molecular docking procedure, using Glide in the standard precision SP mode [30] . The output poses were re-scored with the
Glide extra precision scoring function XP [31] , FlexX [32] and Plants ChemPLP [33] scoring functions.
The rescoring results were combined with a consensus scoring procedure, in which for each scoring function a pose is considered a hit if ranked in the top 25% of the score value range for all the poses of the database. As a further analysis, the molecules matching this criterion for all three scoring functions were re-docked with Glide SP [30] in the RNA binding pocket of the 3KQH crystal structure, which corresponds to the high-affinity open conformation of the enzyme. A final selection of 13 derivatives was made after visual inspection of the docking results. These compounds were purchased and tested in the HCV replicon assay (Table S1 ). Among them, 1a (Figure 3) showed an interesting antiviral profile against HCV replication, with an EC50 value in the low micromolar range ( Table 1 ). The predicted binding mode found for 1a indicates good spatial occupation of the target site, with one aromatic ring in close proximity to Trp501, the piperazine linker filling the central space surrounding
Asn556, and the opportunity of hydrogen-bond formation between one sulfonamido group and Arg393
and Thr411 backbone ( Figure 3 ). Given its potential to inhibit HCV replication, a series of derivatives of 1a was designed and prepared for further investigations.
Chemistry
Compound 1a is characterised by a symmetrical structure, with a central piperazine ring and two aliphatic linkers connected by a sulfonamide group to two equal aromatic systems. The main modifications original structure, by varying the substitutions on the phenyl rings while keeping the central piperazine nucleus, maintaining the original three-carbon saturated linker or symmetrically shortening it to a twocarbon chain. Different commercially available aromatic sulfonyl chlorides (2a-s) and sulphonamide 5
were used to obtain piperazine derivatives 1a-u and 8a-h according to an optimised two-step synthetic pathway (Scheme 1). A further modification was designed to rigidify the three-carbon linker and study the importance of the positive charge/H-bond acceptors of the piperazine amine groups, inserting an amide group in correspondence of piperazine nitrogen atoms, using the scaffold of -alanine (8) as new linker for a third series of symmetrical compounds 11a, d, f-h (Scheme 1).
Scheme 1:
Reagents and conditions: a) i. Et3N, an. DCM, 0 °C, 10 min; ii. NaH, DMF, rt, 1h, followed by 1,3-dibromopropane, 0 °C, 10 min; iii. piperazine, NaHCO3, EtOH, reflux, 24h; iv. LiOH, THF, H2O, 80 °C, on. b) i. NaOH, H2O, 35 °C, 2h; ii. TBTU, HOBt, DiPEA, an. THF, rt, 4h.
The strategy to obtain amine compounds 1a-s and 8a-h began with the preparation of sulfonamides 6a-s and 7a-h, all obtained with a nucleophilic displacement of amino alkylbromides 3-4 and the different sulfonylchlorides. In order to avoid a self-reaction between two molecules of the nucleophile, the amine group of the alkyl bromides was slowly released by the dropwise addition of triethylamine at 0 C. 6u was obtained by treating sulfonamide 5 with sodium hydride, followed by the addition of 1,3-dibromopropane. Final symmetrical products 1a-s, 1u and 8a-h were obtained through the displacement of the intermediate bromide leaving groups by piperazine, using NaHCO3/ethanol as base/solvent system and refluxing the reaction mixture for 24 h. Compound 1t, with a carboxylic function on the aromatic rings, was obtained after basic hydrolysis of ester 1s. Symmetrical amide products 11a, d, f-h were obtained reacting the different sulfonyl chlorides with -alanine 9, with the formation of carboxylic acid intermediates 10a-d, f-h, l, n, which were subsequently used for a coupling reaction with piperazine, using TBTU as coupling agent. With the purpose to further explore the role of the aliphatic linker, its elongation was also envisaged: compound 17 with a four-carbon linker was obtained after optimisation of a four-step synthetic pathway (Scheme 2). Finally, the role of molecular symmetry for antiviral activity was also taken into consideration, and three small series of unsymmetrical compounds were designed and synthesised. All the compounds prepared followed a rational approach guided by the biological results obtained for the previous series of structures. In particular, the presence of two aromatic sulfonamide groups was to be maintained, along with a para hydrophobic substituent in at least one phenyl ring, the central piperazine nucleus and at least one three-carbon linker (Scheme 4). A first series of unsymmetrical compounds 23-35 was designed to maintain the original scaffold while introducing different para hydrophobic substituents in the two aromatic rings, combining together the most successful substitutions previously found (4-chloro, 4-methyl, 4-tert-butyl and 4-trifluoromethyl), along with the unsubstituted phenyl moiety and the biphenyl one. To achieve this result, the two amine groups of piperazine had to be functionalised with two different alkyl bromides: first the pure monosubstitution products were isolated, and then these intermediates were reacted with the second alkyl bromide. A second small series of unsymmetrical derivatives 36a-b, l was designed to maintain the same para hydrophobic substituent in the two aromatic rings, while reducing the length of one linker from three to two methylene groups. Final products 36a-b, l were obtained by reacting mono-substituted intermediates 22 with ethyl bromides 7a-b, l. A third and final series of unsymmetrical structures 37a-c, l, n was planned to functionalise one piperazine amine group to amide, thus partially rigidifying the scaffold, while keeping the overall length of the molecule and the same hydrophobic substituent in the para position of the two aromatic rings. Mono-substituted intermediates 22a-c, l, n were reacted with carboxylic acids 10a-c, l, n, following a TBTU-assisted coupling reaction. Finally, half-molecule derivative 39 was obtained by refluxing intermediate 6a with piperidine 38 in EtOH for 24 hours, using NaHCO3 as base.
Biological activity

HCV replicon and cytostatic assay
All the newly synthesised compounds were evaluated for their potential antiviral activity in the Huh5-2 replicon system ( Table 1 ) [34] . The HCV protease inhibitor telaprevir (VX-950) was included as positive control. 
a EC50 = 50% effective concentration (concentration at which 50% inhibition of virus replication is observed).
b EC90 = 90% effective concentration (concentration at which 50% inhibition of virus replication is observed).
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell).
d The EC50, EC90 and CC50 values are the mean of at least 2 independent experiments, with standard deviations of ±10% of the value quoted unless otherwise stated (mean value ± standard deviations).
e SI = the ratio of CC50 to EC50.
f Concentration needed to reduce rates of helicase-catalysed DNA unwinding by 50% n.d. Not determined
Considering the results obtained for 1a-t, most of the antiviral potential is associated with a hydrophobic substituent in the para position of the two aromatic rings, as can be observed for 1a, 1c, 1l and 1m.
Moreover, moving the original 4-chloro group to position 3 (1i) or 2 (1u) is associated with activity reduction. The lowest EC50 value is reached when a second phenyl group is placed in the position 4 of the two aromatics (1n), although this modification also shows an increased cytotoxic effect. Compounds 1e and 1h, with a para-nitrophenyl and 2-naphthyl aromatic moieties respectively, are associated with an increased toxic effect in comparison with the other analogues in this series, while the removal of the para-substituent or its replacement with methoxy groups leads to loss of activity (1b, d, f, g).
Replacement of the original phenyl rings with heteroaromatic moieties in 1p-r leads as well to loss of activity, and the same effect can be observed for the substitution of the 2-naphthyl group (1h) with a 1-naphthyl in 1o: even though cytotoxicity is reduced, any activity against the viral replication is lost.
Trying to mimic the effect of the 4-nitro group of 1e, a 4-carboxylate function was introduced as aromatic values for most of these compounds are in the range of 1-10 M, suggesting activity retention as a general trend. Nevertheless, in some cases the small modification carried out seems to strongly and unexpectedly affect cytotoxicity, as revealed for 25 and 28-30. In the case of biphenyl products 27, 31, 33 and 34 this cytotoxic effect seems to be at least partially in line with the results obtained for 1n. In the case of unsymmetrical compounds 36a-b, l, in which one aliphatic linker is shortened to two methylene groups, the small change in the molecular structure is associated with a retained antiviral effect, further confirming that symmetry is not required for antiviral activity. Nevertheless, with the exception of 36b, also in this second series of unsymmetrical derivatives the small modification is correlated with an increased cytotoxic effect. Finally, biological results for unsymmetrical compounds 37a-c, l and n, in which one piperazine nitrogen is functionalised to amide, suggest activity retention, with 37a, 37l and 37n showing EC50 values in the low micromolar range, even though the toxic effect seems to be enhanced, particularly for 37l. Data found for 37b, which, as expected, does not show any antiviral activity, confirm the essential role played by a para-hydrophobic aromatic group for the viral replication inhibition.
HCV NS3 helicase enzymatic assays
About half of the newly synthesised compounds were tested for their ability to inhibit HCV NS3 helicasecatalysed nucleic acid unwinding. Somewhat surprisingly, most compounds tested did not effect observed rates of DNA strand separation, even when supplied at concentrations as high as 1 mM ( Table   1) . Primuline [18] and aurintricarboxylic acid [35] were included as positive controls.
The most active compound, 31 (IC50=90±30 µM), was selected for additional analysis along with a compound with intermediate activity, 1l (IC50=310±190), and two compounds that did not inhibit helicase-catalysed DNA unwinding, 1a and 11a ( Figure 5A ). Each compound was tested for its ability to either dislodge HCV helicase from a bound oligonucleotide (
Figure 5B These results suggest that enzymatic in vitro reactions might not be the best assays to detect antivirals that target a helicase. The above observation that a compound that clearly binds directly to NS3h fails to inhibit the enzyme at concentrations where it should be fully bound suggests that assay conditions might prevent the enzyme-inhibitor interaction. For example, the helicase might form oligomers or higher ordered structures when bound to nucleic acids or ATP such that ligand binding is blocked.
Alternatively, the rapid conformational changes that occur while the helicase acts as a molecular motor in these assays might dislodge a bound inhibitor. Based on our results with 31, it is likely that other compounds also bind NS3h with high affinity (examples: 1h, 1l-o, 1s-t, 8a, 8h, 17, 30-31, 34, 36l, 37a, 37l, and 37n). However, testing for at direct interaction between these other compounds and NS3h has been challenging because they do not possess the same optical properties as 31. We are therefore still exploring other possible assays to determine the affinity of other compounds generated in this project for the HCV helicase, many of which are associated with less cytotoxicity in the replicon assay than 31
( Table 1) .
Based on the results obtained so far, some inhibition of the enzyme unwinding activity can be observed with a naphthyl aromatic ring in the symmetrical structure (1h, 1o, 8h), both with a three or two-carbon linker, with a 4-carboxylic or 4-ethoxylate groups (1s-t), with a 4-chlorophenyl system and a two-carbon or four-carbon linker (8a and 17), and with the original three-carbon symmetrical scaffold and a 4-tertbutylphenyl, 4-CF3-phenyl or a 4-biphenyl ring (1l-n). The trend for the enzymatic activity does not seem to parallel the HCV replicon assay, since in this set of data the length of the linker does not play an essential role, even if the presence of a bulky hydrophobic substituent in the para position of the aromatic ring seems relevant for activity. Some ability to inhibit helicase-catalysed unwinding can also be observed in all three series of unsymmetrical structures, in particular with a 4-tert-butyl group in at least one aromatic (30-31, 36l, 37l) , with at least one biphenyl moiety (31, 34, 37n) , or with two equal 4-chlorophenyl substituents in the unsymmetrical amide scaffold (37a).
This data would suggest that the antiviral effect of 31, should be at least in part due to its interference with the NS3 helicase function, and that several commonly used helicase assays grossly underestimate the potency of this, and likely related, compounds. The antiviral effect of the newly prepared structures might alternatively result from the interference with an additional target, viral or cellular. Additional studies aiming to improve the antiviral activity and understand the mechanism of action of these compounds are ongoing and will be reported in due course.
Conclusions
The application of computer-aided techniques to the study of the HCV NS3 helicase led to the identification of one commercial piperazine-based analogue with an antiviral effect against HCV replication in the low micromolar range. Starting from its structure, different modifications were designed and carried out to explore the biological activity associated with the new scaffold. Several analogues of 1a inhibited the HCV subgenomic replicon replication. Different structural modifications were explored to understand the role of aromatic substituents, sulfonamide groups, linker chains, piperazine central nucleus and symmetry of the original molecule. Two equal phenyl rings with a hydrophobic substituent in the para position are essential for antiviral activity, along with the presence of the two sulfonamide groups and the central piperazine nucleus. The length and nature of the two linker chains is also important for activity retention: the presence of at least one three-carbon aliphatic linker is essential, while shortening or elongating the two linkers at the same time is associated with loss of activity. The same effect can be observed with the symmetrical functionalization of piperazine amine groups to amide, by inserting a carbonyl group in the terminal methylene of the two linkers. Replacement of the piperazine central ring with para-phenylendiamine is associated with loss of activity, and activity is lost as well when piperazine central nucleus is replaced with piperidine, maintaining only half of the original scaffold. The overall symmetry of the structure can tolerate small perturbations such as two different para hydrophobic aromatic substituents, or different linker chains. Unsymmetrical derivatives are in general associated with increased cytotoxicity in comparison with their symmetrical counterparts.
In vitro evaluations of some of the newly synthesised compounds show that different inhibit the NS3 helicase activity. In particular, compound 31 bound free helicase with a sub-micromolar dissociation constant, and it influenced the protein's ability to bind nucleic acid substrates needed to stimulate ATP hydrolysis. Even if the antiviral effect of the new structures could be at least partially correlated with inhibition of the NS3 helicase, other viral or cellular targets could still be involved, and the toxicity of activity and biological targets of these compounds is the current focus of ongoing investigations.
Experimental
Materials and methods
All solvents used for chromatography were HPLC grade from Fisher Scientific (UK).
1 H and 13 C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with
Me4Si as internal standard. Mass spectra were determined with a Bruker microTOF spectrometer using electrospray ionization (ESI source). For mass spectra, solutions were made in HPLC grade methanol.
Flash column chromatography was performed with silica gel 60 (230-400mesh) (Merck) and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by illumination under UV light (254 nm). Melting points were determined on an electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 4 Å molecular sieves, under nitrogen. All compounds were more than 95% pure. 
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-tertbutylbenzene-sulfonamide) (1l)
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM- 
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-(trifluoromethyl)-benzene sulfonamide) (1m)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(biphenyl-sulfonamide) (1n)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dinaphthalene-2-sulfonamide (1o)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diquinoline-8-sulfonamide (1p)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dithiophene-2-sulfonamide (1q)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dipyridine-3-sulfonamide (1r)
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2-chlorobenzene-sulfonamide) (1u)
N,N'-(2,2'-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-chlorobenzene sulfonamide) (8a)
N,N'-(2,2'-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-nitrobenzene-sulfonamide) (8e)
N,N'-(2,2'-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(3,4-dimethoxy-benzenesulfonamide)
Synthesis of 3-(N-(3-(4-(3-(4-Carboxyphenylensulfonamido)propyl)piperazin-1-yl)-propyl)-sulfamoyl) benzoic acid (1t)
Compound 1s (0.15 g, 0.3 mmol) was dissolved 3 mL of THF. LiOH monohydrate (0.07 g, 1.7 mmol)
was dissolved in 4 mL of distilled water and added to the THF solution. 
General method for the preparation of N,N'-(piperazine-1,4-diyl)bis(3-oxopropane-)diaryl sulfonamides 11
The different 3-arylsulfonylamino propionic acid 10 (1.3 mmol), TBTU (0.45 g, 1.4 mmol) and HOBt (0.19 g, 1.4 mmol) were suspended in anhydrous THF (9 mL) at r.t. DiPEA (0.7 mL, 4.2 mmol) was then added to the reaction mixture, followed by piperazine (41) (0.05 g, 0.6 mmol). The reaction mixture was left stirring at r.t. for 4 h. The organic solvent was then removed at reduced pressure and the residue was suspended in EtOAc (100 mL). The organic layer was washed with saturated NaHCO3 solution (2 x 70 mL), then with saturated NH4Cl solution (2 x 70 mL) and finally with brine (70 mL). The organic solvent was removed under vacuum after drying over MgSO4. The crude residue was purified by flash column chromatography.
N,N'-(3,3'-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-chlorobenzene-sulfonamide)
Synthesis of {4-[4-(4-tert-Butoxycarbonylamino-butyl)-piperazin-1-yl]-butyl}-carbamic acid
tert-butyl ester (16) Piperazine (0.17 g, 2.1 mmol) and NaHCO3 (0.38, 4.5 mmol) were suspended in 3 mL of absolute ethanol and added dropwise of 79 (1.21 g, 4.5 mmol) diluted in 5 mL of ethanol. The reaction mixture was stirred under reflux for 24 h. The solvent was evaporated under vacuum, and the residue was suspended in DCM (30 mL) and washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL). The organic phase was evaporated at reduced pressure after drying over MgSO4 to give a yellow solid in 70% yield. 
General method for the preparation of unsymmetrical sulfonamides 23-36
A 
General method for the preparation of amides 37
The different 3-arylsulfonylamino propionic acid 10a-c, l, n (1.1 mmol) and TBTU (0.38 g, 1.2 mmol)
were suspended in anhydrous THF (6 mL) at r.t. DiPEA (0.4 mL, 2.4 mmol) was then added to the Four-step, 1-to-5 compound dilution series were prepared for the first screen, to collect data for a more detailed dose-response curve, an eight-step, 1-to-2 dilution series was used. Following assay setup, the microtiter plates were incubated for 72 hours (37 °C, 5% CO2, 95-99% relative humidity). For the evaluation of anti-metabolic effects, the assay medium was aspirated, replaced with 75 μL of a 5% MTS solution in phenol red-free medium and incubated for 1.5 hours (37 °C, 5% CO2, 95-99% relative humidity). Absorbance was measured at a wavelength of 498 nm (Safire2, Tecan), and optical densities
(OD values) were converted to percentage of untreated controls. For the evaluation of antiviral effects, assay medium was aspirated and the cell monolayers were washed with PBS. The wash buffer was aspirated, and 25 μL of Glo Lysis Buffer (Promega) was added allowing for cell lysis to proceed for 5 min at room temperature. Subsequently, 50 μL of Luciferase Assay System (Promega) was added, and the luciferase luminescence signal was quantified immediately (1000 ms integration time/well, Safire, Tecan). Relative luminescence units were converted into percentage of untreated controls.
The EC50 and EC90 (values calculated from the dose-response curve) represent the concentrations at which 50% and 90% inhibition, respectively, of viral replication is achieved. The CC50 (value calculated from the dose-response curve) represents the concentration at which the metabolic activity of the cells is reduced by 50% as compared to untreated cells.
HCV NS3 helicase enzymatic assays
The ability of compounds to inhibit HCV helicase-catalysed nucleic acid unwinding was determined using molecular beacon-based NS3 helicase assays as described by Hanson et al. [39] Reactions contained 25 mM MOPS pH 6.5, 1.25 mM MgCl2, 5% DMSO, 5 µg/ml BSA, 0.01% (v/v) Tween20, 0.05 mM DTT, 5 nM florescent DNA substrate, 12.5 nM NS3h, and 1 mM ATP.
The ability of compounds to displace NS3 from a DNA oligonucleotide was monitored as described by
Mukherjee et al. [40] . Each assay contained 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 0.0025 mg/ml BSA, 0.005% (v/v) Tween20, 0.025 mM DTT and 12.5 nM NS3h.
The ability of NS3 to hydrolyse ATP was monitored as described by Sweeney et al. [41] . Reactions performed in the presence of RNA contained 25 mM MOPS pH 6.5, 1.25 mM MgCl2, 15 µM poly(U) RNA (Sigma), 6 nM NS3h in 5 μg/mL BSA, 0.001% Tween 20.
To determine the compound concentration needed to reduce activity by 50 % (IC50) in each of the above assays, reactions were performed in duplicate two-fold dilution series such that final compound concentrations ranged from 1 mM to 0.78 µM. Data obtained from all reactions within the linear range of the assays were normalized to controls lacking inhibitor (100%) and controls lacking enzyme (0%), and fit to a normalized dose response equation with a variable Hill slope using GraphPad Prism (v. 6).
Average IC50 values ± standard deviations are reported.
To determine the amount of RNA needed for half maximal stimulation of ATP hydrolysis (KRNA), steady state rates were fit to Eq. 1:
V=(Vmax*R/KRNA+R)+ Vb (Eq. 1)
In equation 1, Vmax is maximum ATP hydrolysis rate, R is the concentration of poly(U) RNA, and Vb is the basal rate of ATP hydrolysis in the absence of RNA.
Direct binding assays using intrinsic protein fluorescence were performed as described by Ndjomou where EL=((Kd + L+ E)-sqrt((Kd + L+ E) 2 -4*(L* E)))/2
In eq. 1, L is the total concentration of compound 13, E is the concentration of NS3h, Kd is the dissociation constant describing complex formation, Fe is coefficient describing free protein fluorescence, Fs is a coefficient describing free compound 13 fluorescence, and Fc is a coefficient describing the fluorescence of the protein-ligand complex.
List of abbreviations pegIFN= pegylated-Interferon
DAAs= Direct-Acting-Antivirals
